Summary
The Top 10 Generic Pharmaceutical Companies of 2025 highlight the continued growth and resilience of the global generics industry, led by Sandoz, Sun Pharma, and Fosun Pharma. Collectively, these companies delivered strong generic segment revenues, driven by expanding biosimilars portfolios, complex generics, specialty medicines, and increasing demand for affordable healthcare worldwide. While most companies achieved year-over-year revenue growth, they also faced industry-wide challenges including pricing pressure, regulatory compliance, supply chain complexities, and intensifying competition. The rankings, based on 2024 generic segment revenue, showcase the industry’s strategic focus on innovation, biologics, specialty therapeutics, and global market expansion, reinforcing the critical role of generic pharmaceutical companies in improving patient access to high-quality, cost-effective medicines across the world.
01. Sandoz
Headquarters: Basel, Switzerland
Founded: 1886
Market Cap: $26.20B
Total Employees: 23,000
Stock Exchange: SWX
Primary Segments: Generic Medicines, Biosimilars, Specialty Generics, Hospital Products
Financial Performance
Revenue Trend
Generic Segment Revenue
Sandoz reported generic segment revenue of $10.35B in 2024, representing a 7.4% year-over-year increase, driven by continued growth in its global biosimilars and generics portfolio.
Company Overview
Sandoz is a global leader in generic medicines and biosimilars, serving more than 100 countries with a broad portfolio that includes Erelzi and Hyrimoz. The company focuses on expanding access to affordable medicines while strengthening its position in high-value biologics.
Key Growth Drivers
Expansion of Biosimilars
Continued adoption of biosimilars across oncology, ophthalmology, and immunology supported strong revenue growth.
Growth in Global Generics
New product launches and expanding market penetration across regulated and emerging markets strengthened the company’s generics business.
Strategic Highlights
- Reported $10.35B in generic revenue during 2024.
- Secured European Commission approval for Afqlir (aflibercept), reinforcing its biosimilars leadership.
- Continued expanding its global biosimilars pipeline and manufacturing capabilities.
Challenges
- Pricing pressure across mature generic markets.
- Increasing competition in biosimilars.
- Regulatory compliance and manufacturing requirements.
Outlook
Sandoz is expected to continue expanding its biosimilars and generic medicines portfolio through new product launches, regulatory approvals, and global market expansion.
Editor’s Take
Sandoz remains the global benchmark for generic medicines and biosimilars, combining industry-leading scale with continuous innovation to improve access to affordable healthcare worldwide.
02. Sun Pharma
Headquarters: Mumbai, India
Founded: 1983
Market Cap: $44.28B
Total Employees: 43,000
Stock Exchange: NSE
Primary Segments: Generic Medicines, Specialty Pharmaceuticals, APIs, Branded Medicines, Consumer Healthcare
Financial Performance
Revenue Trend
Generic Segment Revenue
Sun Pharma reported generic segment revenue of $6.26B in 2024, reflecting a 7.5% year-over-year increase, driven by strong global demand for generic medicines and continued growth in its specialty portfolio.
Company Overview
Sun Pharma is India’s largest pharmaceutical company and one of the world’s leading generic drug manufacturers. The company operates in more than 100 countries with a diversified portfolio that includes Absenz and Betavert, alongside specialty medicines across dermatology, ophthalmology, and oncology.
Key Growth Drivers
Growth in Generic Medicines
Strong demand across regulated and emerging markets, supported by new product launches, contributed to steady revenue growth.
Expansion of Speciality Portfolio
Continued investment in speciality therapies strengthened the company’s presence in high-value therapeutic areas and diversified its revenue base.
Strategic Highlights
- Reported $6.26B in generic revenue during 2024.
- Signed a patent licensing agreement with Takeda to commercialize Voltapraz (Vonoprazan) in India.
- Continued expanding its specialty medicines portfolio through strategic investments and product launches.
Challenges
- Pricing pressure in global generic markets.
- Regulatory compliance across manufacturing facilities.
- Increasing competition in specialty medicines and biosimilars.
Outlook
Sun Pharma is expected to strengthen its leadership through continued expansion of its generics and specialty medicines portfolio while increasing its global market presence.
Editor’s Take
Sun Pharma continues to lead the Indian pharmaceutical industry through its diversified portfolio, global reach, and growing investment in specialty medicines, positioning the company for sustained long-term growth.
03. Fosun Pharma
Headquarters: Shanghai, China
Founded: 1978
Market Cap: $10.69B
Total Employees: ~40,600
Stock Exchange: SHA
Primary Segments: Generic Medicines, Prescription Pharmaceuticals, Medical Devices, Diagnostics, Healthcare Services
Financial Performance
Revenue Trend
Generic Segment Revenue
Fosun Pharma reported generic segment revenue of $5.60B in 2024, reflecting a 3.7% year-over-year decline, primarily due to moderate sales performance across its pharmaceutical business.
Company Overview
Fosun Pharma is one of China’s leading healthcare companies, offering a diversified portfolio of generic and prescription medicines, medical devices, diagnostics, and healthcare services. Its generics portfolio includes products such as Han Da Yuan and Han Qu You, while the company continues to expand its innovative medicines and biologics business.
Key Growth Drivers
Diversified Pharmaceutical Portfolio
A broad portfolio of generic and prescription medicines across multiple therapeutic areas continued to support the company’s overall business performance.
Investment in Innovation
Continued investment in biologics, specialty medicines, and research & development strengthened Fosun Pharma’s long-term growth strategy.
Strategic Highlights
- Reported $5.60B in generic revenue during 2024.
- Received NMPA approval for Daxxify in China in September 2024.
- Continued expanding its biologics pipeline and strategic partnerships.
Challenges
- Moderate pharmaceutical sales during 2024.
- Pricing pressure in China’s pharmaceutical market.
- Increasing regulatory and compliance requirements.
Outlook
Fosun Pharma is expected to strengthen its pharmaceutical business by expanding its portfolio of innovative medicines, biologics, and generic products while increasing its international presence.
Editor’s Take
Fosun Pharma continues to build a strong position in the global healthcare industry through its diversified pharmaceutical business, growing innovation pipeline, and expanding biologics portfolio, supporting long-term sustainable growth.
04. Viatris
Headquarters: Pennsylvania, United States
Founded: 2020
Market Cap: $11.82B
Total Employees: 32,000
Stock Exchange: NASDAQ
Primary Segments: Generic Medicines, Branded Pharmaceuticals, Complex Generics, Biosimilars, Specialty Medicines
Financial Performance
Revenue Trend
Generic Segment Revenue
Viatris reported generic segment revenue of $5.49B in 2024, reflecting a 1.7% year-over-year decline, primarily due to lower international sales and continued pricing pressure in global generic markets.
Company Overview
Viatris is a global healthcare company specializing in generic, branded, and complex medicines. Formed through the merger of Mylan and Upjohn, the company serves patients in more than 165 countries with a broad portfolio that includes Abiraterone and Acamprosate, while expanding its presence in biosimilars and specialty pharmaceuticals.
Key Growth Drivers
Diversified Global Portfolio
Viatris continued leveraging its extensive portfolio of generic and branded medicines across developed and emerging markets, supporting long-term business stability.
Expansion of Complex Medicines
The company maintained its focus on complex generics and biosimilars, strengthening its pipeline through continued investment in research and product development.
Strategic Highlights
- Reported $5.49B in generic revenue during 2024.
- Announced positive Phase III clinical trial results for Effexor in Japanese adults with Generalized Anxiety Disorder (GAD) in October 2024.
- Continued expanding its portfolio of complex generics and biosimilars.
Challenges
- Lower international generic sales.
- Pricing pressure across mature pharmaceutical markets.
- Increasing competition in specialty medicines and biosimilars.
Outlook
Viatris is expected to strengthen its global position by expanding its complex generics, biosimilars, and specialty medicines portfolio while improving operational efficiency and global market reach.
Editor’s Take
Viatris remains one of the world’s largest generic pharmaceutical companies, combining a broad global footprint with a diversified product portfolio. Continued investment in complex medicines and biosimilars positions the company for sustainable long-term growth despite ongoing market challenges.
05. Fresenius Kabi
Headquarters: Bad Homburg, Germany
Founded: 1999
Market Cap: $30.45B
Total Employees: ~176,200
Stock Exchange: ETR
Primary Segments: Generic Medicines, Biosimilars, Clinical Nutrition, Intravenous Therapies, Medical Devices
Financial Performance
Revenue Trend
Generic Segment Revenue
Fresenius Kabi reported generic segment revenue of $3.99B in 2024, reflecting a 5.5% year-over-year decline, primarily due to lower biosimilar sales despite stable demand for its hospital medicines portfolio.
Company Overview
Fresenius Kabi is a global healthcare company and a subsidiary of Fresenius SE & Co. KGaA, specializing in generic injectable medicines, biosimilars, clinical nutrition, infusion therapies, and medical technologies. Its biosimilars portfolio includes products such as Adalimumab, Pegfilgrastim, Tocilizumab, and Ustekinumab, serving hospitals and healthcare providers worldwide.
Key Growth Drivers
Leadership in Hospital Medicines
Strong demand for injectable generic medicines and hospital-based therapies continued to support the company’s global business.
Expansion of Biosimilars
Fresenius Kabi continued investing in biosimilars across oncology and immunology to strengthen its long-term growth pipeline.
Strategic Highlights
- Reported $3.99B in generic revenue during 2024.
- Launched a generic Epinephrine Injection (1 mg/1 mL) in the U.S. in December 2024.
- Continued expanding its biosimilars portfolio and global manufacturing capabilities.
Challenges
- Lower biosimilar sales during 2024.
- Pricing pressure across global generic markets.
- Increasing regulatory compliance and manufacturing requirements.
Outlook
Fresenius Kabi is expected to strengthen its position through continued expansion of its biosimilars portfolio, injectable medicines business, and hospital-focused healthcare solutions.
Editor’s Take
Fresenius Kabi remains a leading provider of hospital medicines and biosimilars, supported by a diversified healthcare portfolio and strong global presence. Continued investment in biologics and essential medicines positions the company for sustainable long-term growth.
06. Aurobindo Pharma
Headquarters: Hyderabad, India
Founded: 1986
Market Cap: $7.08B
Total Employees: ~27,700
Stock Exchange: NSE
Primary Segments: Generic Medicines, Active Pharmaceutical Ingredients (APIs), Injectable Pharmaceuticals, Specialty Medicines, Biosimilars
Financial Performance
Revenue Trend
Generic Segment Revenue
Aurobindo Pharma reported generic segment revenue of $3.61B in 2024, reflecting a 10.9% year-over-year increase, driven by strong global demand for generic medicines and growth across regulated markets.
Company Overview
Aurobindo Pharma is one of India’s largest generic pharmaceutical manufacturers, offering a broad portfolio of generic medicines, APIs, injectables, specialty pharmaceuticals, and biosimilars. Its global product portfolio includes Zovirax and Xanax XR, while its vertically integrated manufacturing model supports operations across more than 150 countries.
Key Growth Drivers
Strong Global Generics Business
Continued product launches and increasing demand across North America, Europe, and emerging markets supported steady growth in the company’s generics business.
Expansion of Biosimilars
Through its subsidiary CuraTeQ Biologics, Aurobindo strengthened its biosimilars portfolio while expanding into high-value specialty therapies.
Strategic Highlights
- Reported $3.61B in generic revenue during 2024.
- CuraTeQ Biologics received UK MHRA approval for Bevqolva in December 2024.
- Continued expanding its injectable medicines, biosimilars, and specialty pharmaceutical portfolio.
Challenges
- Pricing pressure across global generic markets.
- Increasing regulatory compliance requirements.
- Rising competition in specialty medicines and biosimilars.
Outlook
Aurobindo Pharma is expected to continue strengthening its global generics business while expanding its presence in biosimilars, injectables, and specialty pharmaceuticals through continued investment and product innovation.
Editor’s Take
Aurobindo Pharma continues to strengthen its position as a leading global generics manufacturer through its vertically integrated operations, diversified product portfolio, and growing biosimilars business. Its continued focus on innovation and international expansion supports sustainable long-term growth.
07. Teva Pharmaceuticals
Headquarters: Tel Aviv, Israel
Founded: 1944
Market Cap: $23.26B
Total Employees: 37,000
Stock Exchange: TLV
Primary Segments: Generic Medicines, Specialty Pharmaceuticals, Biosimilars, Active Pharmaceutical Ingredients (APIs)
Financial Performance
Revenue Trend
Generic Segment Revenue
Teva Pharmaceuticals reported generic segment revenue of $3.59B in 2024, reflecting a 14.7% year-over-year increase, driven by strong demand for generic medicines, successful product launches, and continued expansion of its biosimilars business.
Company Overview
Teva Pharmaceuticals is one of the world’s largest manufacturers of generic medicines, offering a diversified portfolio of generics, specialty pharmaceuticals, biosimilars, and APIs. Its portfolio includes products such as Acitretin, Acyclovir, and Capecitabine, while serving patients across more than 60 countries through a strong global manufacturing and distribution network.
Key Growth Drivers
Growth in Global Generics
Strong demand across regulated and emerging markets, supported by new product launches and portfolio expansion, continued to drive growth in Teva’s generics business.
Expansion of Biosimilars
The company strengthened its biosimilars portfolio through strategic collaborations and continued investment in oncology and immunology therapies.
Strategic Highlights
- Reported $3.59B in generic revenue during 2024.
- Expanded its oncology biosimilars partnership with mAbxience in October 2024.
- Continued investing in specialty medicines, biosimilars, and differentiated generic products.
Challenges
- Pricing pressure in global generic pharmaceutical markets.
- Increasing regulatory compliance requirements.
- Rising competition in biosimilars and specialty medicines.
Outlook
Teva is expected to strengthen its leadership in generic medicines by expanding its biosimilars portfolio, launching differentiated products, and increasing its presence across key global markets.
Editor’s Take
Teva Pharmaceuticals remains one of the global leaders in generic medicines, supported by its extensive manufacturing network, diversified portfolio, and growing biosimilars business. Continued investment in innovation and strategic partnerships positions the company for sustainable long-term growth.
08. Dr. Reddy’s Laboratories
Headquarters: Hyderabad, India
Founded: 1984
Market Cap: $11.61B
Total Employees: ~27,800
Stock Exchange: NSE
Primary Segments: Generic Medicines, Pharmaceutical Services, APIs, Biosimilars, Specialty Pharmaceuticals
Financial Performance
Revenue Trend
Generic Segment Revenue
Dr. Reddy’s Laboratories reported generic segment revenue of $3.51B in 2024, reflecting an 11.5% year-over-year increase, driven by strong international sales, new product launches, and continued expansion of its global generics portfolio.
Company Overview
Dr. Reddy’s Laboratories is a leading Indian multinational pharmaceutical company specializing in generic medicines, biosimilars, APIs, and pharmaceutical services. Its portfolio includes products such as Lenalidomide, Treprostinil, and Regadenoson, while serving patients across more than 60 countries through a diversified global business.
Key Growth Drivers
Expansion of Global Generics
Strong demand across North America, Europe, and emerging markets, supported by new product launches, continued to drive growth in the company’s generics business.
Growth in Biosimilars
Continued investment in biosimilars and biologics strengthened the company’s long-term growth strategy while expanding its presence in high-value therapeutic areas.
Strategic Highlights
- Reported $3.51B in generic revenue during 2024.
- Partnered with Senores Pharmaceuticals to launch Ivermectin (Stromectol) in the U.S. in November 2024.
- Continued expanding its biosimilars pipeline and global generics portfolio.
Challenges
- Pricing pressure across global generic markets.
- Increasing regulatory compliance requirements.
- Rising competition in biosimilars and specialty pharmaceuticals.
Outlook
Dr. Reddy’s is expected to strengthen its global leadership through continued expansion of its generics and biosimilars portfolio, supported by strategic partnerships, product launches, and sustained investment in innovation.
Editor’s Take
Dr. Reddy’s Laboratories continues to be one of India’s leading pharmaceutical companies, combining a strong global generics business with growing expertise in biosimilars and specialty medicines. Its diversified international presence and innovation-driven strategy position the company for sustainable long-term growth.
09. Cipla
Headquarters: Mumbai, India
Founded: 1935
Market Cap: $13.63B
Total Employees: ~30,300
Stock Exchange: NSE
Primary Segments: Generic Medicines, Branded Pharmaceuticals, APIs, Respiratory Therapies, Chronic Care, Consumer Health
Financial Performance
Revenue Trend
Generic Segment Revenue
Cipla reported generic segment revenue of $3.15B in 2024, reflecting a 5.6% year-over-year increase, driven by continued growth in its chronic therapies portfolio and strong demand across key international markets.
Company Overview
Cipla is a leading global pharmaceutical company recognized for its expertise in generic medicines, branded formulations, and respiratory therapies. The company’s portfolio includes Foracort and Budecort, while its operations span more than 80 countries, supporting patients with affordable and high-quality healthcare solutions.
Key Growth Drivers
Leadership in Respiratory Care
Strong demand for respiratory products and inhalation therapies continued to drive growth, reinforcing Cipla’s leadership in this therapeutic segment.
Expansion of Chronic Therapies
The company strengthened its chronic care portfolio across cardiology, diabetes, and other long-term disease segments, supporting consistent revenue growth.
Strategic Highlights
- Reported $3.15B in generic revenue during 2024.
- Signed a non-exclusive licensing agreement with Takeda to commercialize Vonoprazan in India in June 2024.
- Continued expanding its respiratory and chronic care portfolio across global markets.
Challenges
- Pricing pressure across global generic markets.
- Increasing regulatory compliance requirements.
- Rising competition in respiratory and chronic therapy segments.
Outlook
Cipla is expected to strengthen its global position through continued expansion of its respiratory franchise, chronic care portfolio, and differentiated generic medicines while investing in innovation and strategic partnerships.
Editor’s Take
Cipla remains one of India’s most respected pharmaceutical companies, combining leadership in respiratory care with a diversified global generics business. Its focus on chronic therapies, innovation, and international expansion positions the company for sustainable long-term growth.
10. Lupin
Headquarters: Mumbai, India
Founded: 1968
Market Cap: $9.84B
Total Employees: ~24,000
Stock Exchange: NSE
Primary Segments: Generic Medicines, Branded Pharmaceuticals, APIs, Biosimilars, Specialty Pharmaceuticals
Financial Performance
Revenue Trend
Generic Segment Revenue
Lupin reported generic segment revenue of $2.59B in 2024, reflecting a 10.2% year-over-year increase, driven by strong growth in the U.S. generics market and expanding demand for its differentiated pharmaceutical portfolio.
Company Overview
Lupin is a leading Indian multinational pharmaceutical company specializing in generic medicines, branded formulations, APIs, biosimilars, and specialty pharmaceuticals. The company’s portfolio includes products such as Ab-Next, Abdowell, and Adhero, while maintaining a strong presence across more than 100 countries.
Key Growth Drivers
Growth in U.S. Generics
Strong demand across the U.S. market, supported by new product launches and portfolio expansion, remained a key contributor to the company’s revenue growth.
Expansion of Complex Generics
Continued investment in complex generics, specialty medicines, and biosimilars strengthened Lupin’s competitive position and supported long-term business growth.
Strategic Highlights
- Reported $2.59B in generic revenue during 2024.
- Received tentative U.S. FDA approval for Raltegravir Tablets in November 2024.
- Continued expanding its portfolio of complex generics, biosimilars, and specialty medicines.
Challenges
- Pricing pressure across global generic pharmaceutical markets.
- Increasing regulatory compliance requirements.
- Rising competition in specialty medicines and biosimilars.
Outlook
Lupin is expected to strengthen its global presence by expanding its complex generics, biosimilars, and specialty medicines portfolio while continuing to invest in research, innovation, and international market expansion.
Editor’s Take
Lupin has established itself as one of India’s leading pharmaceutical companies through its diversified generics business, growing specialty portfolio, and expanding global footprint. Its continued focus on innovation, complex generics, and biosimilars positions the company for sustainable long-term growth in the evolving global pharmaceutical market.
Criteria
- Only publicly listed companies are included in this report.
- Companies are ranked based on their total revenue.
